Gene therapy developers can expect less hand-holding from OTAT
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy